In a paper published in Science Bulletin, a Chinese team of scientists reported a comprehensive proteogenomic analysis of 101 Chinese AML patients, including proteomic and phosphoproteomic analyses and an in vitro drug sensitivity analysis in addition to whole exome and transcriptome sequencing. They integrated multi-omic data to predict and validate patient prognosis and drug sensitivity. They revealed three subtypes based on proteome, where S-II and S-III characterized mainly by metabolism and could benefit from Allogeneic haematopoietic stem cell transplantation, but S-I enriched in tumour proliferation could not. Further correlation analysis of 77 drugs sensitivity with proteomic and phosphoproteomic data uncovered the therapeutic strategies of cytarabine-disulfiram and PI3K inhibitor-PDK inhibitor combinations.  Overall, the research provide a resource for understanding the molecular alterations in AML and developing potential therapeutic strategies.

A research team led by Prof. Baowen Zhou has developed a novel Zn-decorated GaN nanowire catalyst that converts CO₂ and H₂O into methane (CH₄) and hydrogen peroxide (H₂O₂) using light. The main research was carried out by Dr. Muhammad Salman Nasir, achieving methane production rates of 189 mmol g^–1 h^–1 with a selectivity of 93.6% and excellent long-term stability for over 80 hours. This breakthrough provides a sustainable pathway to carbon-neutral energy and industrial chemical production.

Researchers from the Harbin Institute of Technology (HIT) have proposed a 7-axis synchronization strategy for simultaneously realizing high accuracy, high efficiency and large scale in multi-axis linkage laser texturing of freeform surface, based on the unified control of a 5-axis linkage motion platform with a 2-dimensional galvanometer. And corresponding specialized machine tool implemented with the proposed strategy has been developed, which shows significantly promoted performance of laser texturing on freeform surface than the traditional 5-axis linkage strategy.

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy. This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD positive but BRCA wild-type, a demographic less extensively explored in previous research. The primary goal was to assess the 1-year progression-free survival (PFS) rate of olaparib maintenance therapy in this specific patient group, offering insights into its potential as a therapeutic option.